J Neuropsychiatry Clin Neurosci 11:19-31, February 1999
© 1999 American Psychiatric Press, Inc.
The Neurobiology and Pharmacotherapy of Alzheimer's Disease
Olivier Felician, M.D. and
Thomas A. Sandson, M.D.
Received December 4, 1997; revised March 20, 1998; accepted May 13, 1998. From the Behavioral Neurology Unit, Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215. Send correspondence Dr. Sandson at the above address.
Alzheimer's disease (AD), the most common cause of dementia, has become a major public health concern as our population ages. In recent years, AD has attracted the attention of a wide range of biological disciplines, and substantial progress has been made in understanding the mechanisms of neurodegeneration in AD. Four different genes have now been associated with AD and are providing insights into the pathogenesis of the disease. The roles of beta-amyloid, tau, hormonal changes, inflammation, and oxidative stress in the neurodegeneration of AD are also being delineated. Based on these discoveries, rational therapeutic strategies are developing rapidly. The authors review these and other recent advances in the neurobiology and pharmacotherapy of AD.
Key Words: Alzheimer's Disease • Amyloid Protein • Tau Protein • Apolipoprotein E • Presenilin • Oxidative Stress
This article has been cited by other articles:
|
|
|
|
 
P J Visser, F R J Verhey, P A M Hofman, P Scheltens, and J Jolles
Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment
J. Neurol. Neurosurg. Psychiatry,
April 1, 2002;
72(4):
491 - 497.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1999
American Neuropsychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
